touchEXPERT OPINIONS HR+/HER2- advanced breast cancer: How do the latest data on CDK4/6 inhibitors inform clinical decision-making?
Watch leading experts consider how the latest data on CDK4/6 inhibitors in the treatment of HR+/HER2- advanced breast cancer may shape clinical practice.
How can biomarkers inform treatment selection in HR+/HER2- advanced breast cancer?
Dr Luca Malorni discusses how resistance to CDK4/6 inhibitors develops in patients with HR+/HER2- advanced breast cancer and how molecular biomarkers may be used in the future to optimize treatment choices.
1/3 Next InterviewIn this interview, Dr Luca Malorni answers the following questions:
- Why are biomarkers needed for CDK4/6 inhibitor therapy in HR+/HER2- advanced breast cancer?
- What mechanisms are believed to be implicated in resistance to CDK4/6 inhibitors?
- What is the evidence to date for possible biomarkers of response to CDK4/6 inhibitors?
- How could new biomarker testing be implemented into clinical practice?
Luca Malorni is a Senior Medical Oncologist and Director of the Translational Research Unit at the Hospital of Prato, Prato, Italy. read more
Dr Malorni’s expertise is in translational and clinical research. His education and training at the University of Naples, Naples, Italy and Baylor College of Medicine, Houston, TX, USA, were centred around breast cancer management “from bench to bedside”, with a particular focus on endocrine resistance.
Dr Luca Malorni discloses: Research funding from Novartis and Pfizer. Speaker/consultant for Lilly, Novartis and Pfizer.
What is the relevance of intrinsic HR+/HER2- breast cancer subtypes in clinical decision-making?
Prof. Aleix Prat presents the most recent data on the prognostic value of molecular intrinsic subtyping in HR+/HER2- breast cancer and its value in predicting response to CDK4/6 inhibitors.
2/3 Next InterviewIn this interview, Prof. Aleix Prat answers the following questions:
- What are the different intrinsic subtypes of breast cancer?
- What is the prognostic value of intrinsic subtypes in HR+/HER2- breast cancer?
- What is the evidence for efficacy of CDK4/6 inhibitors in different intrinsic subtypes in HR+/HER2- breast cancer?
- How can intrinsic subtypes help inform treatment selection in HR+/HER2- breast cancer?
Aleix Prat is Head of the Medical Oncology Department at Hospital Clínic Barcelona, Barcelona, Spain. He is also Tenure-Track Professor at the University of Barcelona. read more
From a research perspective, Prof. Prat has created a new laboratory at the Institut d’investigacions biomèdiques August Pi i Sunyer (IDIBAPS; i.e. Hospital Clínic’s research centre) that uses genomic data to guide clinical trial design and biomarker development, and to study the molecular mechanisms of drug sensitivity to identify optimal treatment regimens for patients with cancer.
Prof. Prat has (co)authored approximately 184 peer-reviewed papers. In 2012, he received the International Award for Breast Cancer Research in Padova, Italy. He is the principal investigator of several trials and a member of the Executive Committee of the Breast International Group (BIG). Since 2019, he has been President of the Board of Directors of the SOLTI Spanish breast cancer cooperative group.
Prof. Aleix Prat discloses:
Personal financial interests: Lecture fees from Amgen, BMS, Daiichi Nanostring Technologies, Novartis, Pfizer, Roche and Sankyo. Advisory role/consultancy for Amgen, BMS, Guardan Health, Lilly, MSD, Novartis, Oncolytics Biotech, Peptomyc, Pfizer, Puma and Roche. Leadership role with Reveal Genomics.
Institutional financial interests: Contracted research for Astellas, Boehringer, Celgene, Medica Scientia Innovation Research, Nanostring Technologies, Novartis, Pfizer, Roche and Sysmex Europa GmbH. Lecture fees from Nanostring Technologies. Clinical trials for Amgen, Boehringer, Daiichi Sankyo, Lilly, Novartis and Roche.
Leadership roles: Executive boards for Breast International Group, Reveal Genomics and SOLTI cooperative group. Patronage committee for Actitud Frente al Cáncer Foundation and SOLTI Foundation.
How do patient and disease characteristics impact treatment choice and response to CDK4/6 inhibitor therapy?
Dr Barbara Pistilli presents the most recent clinical evidence on the effect of different patient characteristics, including menopausal status, age, sensitivity to endocrine therapy and metastases, on CDK4/6 inhibitor therapy in HR+/HER2- breast cancer.
3/3 Leave Feedback
In this interview, Dr Barbara Pistilli answers the following questions:
- Does patient age make a difference to the clinical benefit and tolerability experienced with CDK4/6 inhibitor therapy?
- What do clinical trial data tell us about the influence of menopausal status on the efficacy of different CDK4/6 inhibitors?
- How does previous sensitivity to endocrine therapy impact the efficacy of CDK4/6 inhibitors?
- What is the impact of bone and visceral metastases on the efficacy of CDK4/6 inhibitors?
- What is the evidence for CDK4/6 inhibitors in patients with HR+/HER2- breast cancer with CNS metastases?
Barbara Pistilli is Head of the Breast Cancer Unit at Gustave Roussy, Villejuif, France. She leads the CANTO COMPLETE PROGRAM, which aims to identify prevalence and predictors of non-adherence to endocrine therapy in young patients with breast cancer. read more
Dr Pistilli also co-leads a large programme aiming to characterize mechanisms of action and biomarkers of response and resistance of antibody-drug conjugates. Her clinical research programme also includes genomic profiling and systemic treatment of breast cancer local recurrence.
Dr Barbara Pistilli discloses: Consulting/advisor for Myriad Genetics, Novartis, Pierre Fabre and Puma Biotechnology. Personal fees from AstraZeneca, MSD Oncology, Novartis and Pfizer. Research funding from AstraZeneca, Daiichi, Merus, Novartis, Pfizer and Puma Biotechnology.
Overview & Learning Objectives
Overview
In this activity, leading experts in breast cancer provide updates on biomarkers for response to CDK4/6 inhibitors, the prognostic value of intrinsic subtypes and clinical characteristics which can help guide treatment decisions.
Learning Objectives
After watching this activity, participants should be better able to:
- Recall the most recent data on potential biomarkers of response to CDK4/6 inhibitors
- Evaluate the impact of intrinsic subtypes on treatment selection and outcomes in advanced breast cancer
- Discuss how different patient characteristics may impact choice of CDK4/6 inhibitor for patients with HR+/HER2- advanced breast cancer
Register to touchONCOLOGY for FREE
- Peer reviewed journals and expert opinion
- Interactive CME and e-learning modules
- Video conference highlights
